T 1724/19 (GDF-15 and metabolic disorders/AMGEN) of 21.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T172419.20211021
- Date of decision
- 21 October 2021
- Case number
- T 1724/19
- Petition for review of
- -
- Application number
- 12761825.4
- IPC class
- A61P 3/00A61K 38/18
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
- Applicant name
- Amgen Inc.
- Opponent name
- NGM Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Novelty - (yes)
Inventive step - (no)
Auxiliary request 2 filed during oral proceedings - exceptional circumstances (no)
Filing of new document after summons - exceptional circumstances (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.